Which companies have Pfizer, Gilead Sciences, Amgen, AstraZeneca, etc. acquired since 2022?

On August 8, Pfizer announced that it would acquire Global Blood Therapeutics for about $5.

Since 2022, global pharmaceutical companies including Pfizer, Gilead Sciences, AstraZeneca, Amgen, Bristol-Myers Squibb, GlaxoSmithKline and others have announced acquisition deals to expand their product pipelines

Acquirer: Pfizer

Acquirer: Pfizer

Acquired parties: GBT, Biohaven, ReViral

Acquired parties: GBT, Biohaven, ReViral

According to public information, since 2022, Pfizer has announced three agreements to acquire companies

On August 8, Pfizer and Global Blood Therapeutics (GBT) announced an agreement, whereby Pfizer would acquire the latter for about $5.

For the treatment of sickle cell anemia in adults and adolescents over the age of 12, and won the Galen Prize, known as the "Nobel Prize in Medicine" in 2021

On May 10, Pfizer and Biohaven Pharmaceutical announced that they had reached an agreement whereby Pfizer would acquire Biohaven for a total of approximately $11.

Pfizer to buy Biohaven for about $11.

Pfizer to acquire Pfizer for $525 million focused on discovery and development of novel antiviral therapies targeting respiratory syncytial virus (RSV)

Acquirer: Gilead Sciences

Acquirer: Gilead Sciences

Acquired: MiroBio Corporation

Acquired: MiroBio Corporation

On August 4, Gilead Sciences announced that it had reached a definitive agreement with MiroBio to acquire the latter for about $405 million

The latter will be acquired for approximately US$405 million.

Acquirer: Amgen

Acquired: ChemoCentryx Corporation

Acquired: ChemoCentryx Corporation

On August 4, Amgen and ChemoCentryx announced that they had reached an agreement, and Amgen would spend about $3.

Amgen to acquire the latter for about $3.

Acquirer: AstraZeneca

Acquired: TeneoTwo Corporation

Acquired: TeneoTwo Corporation

On July 6, AstraZeneca announced that it intends to acquire the biotechnology company TeneoTwo and will obtain TNB-486, a bispecific molecular therapy in Phase 1 clinical trials

bispecific molecular therapy

TNB-486 is a T cell linker therapy that simultaneously targets the CD19 antigen on the surface of B cells and the CD3 receptor on the surface of T cells

It can simultaneously target the CD19 antigen on the surface of B cells and the CD3 receptor on the surface of T cells

Acquirer: Ipsen

Acquired: Epizyme Corporation

Acquired: Epizyme Corporation

On June 28, Ipsen (Ipsen) and Epizyme announced that the two sides had reached an agreement, Ipsen will spend about 247 million US dollars to acquire the latter

The company's tazemetostat is a "first-in-class" EZH2 inhibitor in patients with EZH2-mutated relapsed or refractory follicular lymphoma and soft tissue sarcoma

Acquirer: Bristol-Myers Squibb (BMS)

Acquirer: Bristol-Myers Squibb (BMS)

Acquired: Turning Point Corporation

Acquired: Turning Point Corporation

On June 4, Bristol-Myers Squibb Company and Turning Point Therapeutics announced that they had reached an agreement whereby Bristol-Myers Squibb Company would spend more than $4 billion to acquire the latter

Bristol-Myers Squibb to spend more than $4 billion to acquire Bristol-Myers Squibb, which develops precision therapies that target common mutations associated with cancer The drug has received three breakthrough therapy designations from the FDA

Acquirer: GlaxoSmithKline (GSK)

Acquirer: GlaxoSmithKline (GSK)

Acquired: Affinivax, Sierra Oncology

Acquired: Affinivax, Sierra Oncology

On May 31, GSK announced that it had reached an agreement with Affinivax to acquire the latter for $3.

The vaccine candidate AFX3772, which is planned to acquire the latter company Affinivax for US$3.

GSK will spend about US$1.
9 billion to acquire the latter.
The acquisition was completed in July this year.
The product pipeline includes JAK inhibitors, selective BRD4 BET inhibitors, Chk1 small molecule inhibitors, etc.

Acquirer: Regeneron

Acquirer: Regeneron

Acquired: Checkmate Corporation

Acquired: Checkmate Corporation

On April 20, Regeneron and Checkmate Pharmaceuticals announced that they had reached an agreement for Regeneron to acquire the latter for about $250 million, which was completed in May this year
.
Checkmate's lead product candidate, vidutolimod, is a new-generation Toll-like receptor 9 (TLR9) agonist currently in Phase 2 clinical trials for indications including melanoma, metastatic prostate cancer, Merkel cell carcinoma, etc.

.

The lead product candidate, vidutolimod, is a new generation of Toll-like receptor 9 (TLR9) agonists and is currently in Phase 2 clinical trials.

As a non-infectious virus-like particle (VLP) carrying the CpG-A DNA sequence, vidutolimod acts through two complementary mechanisms: First, the VLP activates an immune response leading to the production of antibodies, and the Receptor delivers VLPs to plasmacytoid dendritic cells (pDCs) and other immune cells, which provides an initial stimulatory signal to pDCs and brings CpG-A into pDCs where they can interact with TLR9 Second, CpG-A stimulates TLR9, inducing pDCs to release higher levels of IFN-α and other type I interferons than other innate immune activators, resulting in stronger antitumor T cell responses
.

Acquirer: AbbVie

Acquirer: AbbVie

Acquired: Syndesi Corporation

Acquired: Syndesi Corporation

On March 1, AbbVie announced that it had completed the acquisition of Syndesi Therapeutics for about $1 billion to expand its neuroscience product portfolio
.
The acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of synaptic vesicle protein 2A (SV2A), including the lead molecule SDI-118
.
Products of this mechanism are currently being evaluated for the treatment of cognitive impairment and a range of other neuropsychiatric and neurodegenerative diseases such as Alzheimer's disease and major depressive disorder
.
SDI-118 is currently undergoing a Phase 1b clinical study in subjects with cognitive decline.
The drug is expected to target nerve endings to enhance synaptic efficiency, and synaptic dysfunction is considered to be recognized in many neuropsychiatric and neurodegenerative diseases The basis of cognitive impairment
.

The acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of synaptic vesicle 2A (SV2A)

Acquirer: Janssen Corporation

Acquirer: Janssen Corporation

Acquired: Anakuria Therapeutics

Acquired: Anakuria Therapeutics

On February 2, Navitor Pharmaceuticals announced that its Anakuria Therapeutics company has been acquired by Johnson & Johnson's Janssen to advance the development of its novel selective mTORC1 inhibitor
.
The mTORC1 complex controls the rate and ability of cells to synthesize proteins and other cellular components
.
Increased mTORC1 activity causes protein misfolding and drives cellular stress, inflammation and fibrosis, leading to a wide range of diseases of aging
.

to advance the development of its novel selective mTORC1 inhibitor

Among them, Anakuria's investigational therapy AT-20494 is an oral small molecule that selectively inhibits the activity of mTORC1, a major regulator of cellular metabolism, which is used in autosomal dominant polycystic kidney disease (ADPKD).
Overactive in a variety of chronic diseases
.
According to the press release, AT-20494 has the potential to be a "first-in-class" therapy for ADPKD
.

AT-20494 has the potential to be a "first-in-class" therapy for ADPKD

Acquirer: UCB (UCB)

Acquirer: UCB (UCB)

Acquired: Zogenix Corporation

Acquired: Zogenix Corporation

On January 19, UCB announced that it had reached an acquisition agreement with Zogenix, and planned to spend about $1.
9 billion to acquire Zogenix
.
UCB will acquire Fintepla (fenfluramine) oral solution while expanding its clinical development pipeline for the treatment of epilepsy and rare diseases
.
In March of this year, UCB announced that it had completed the acquisition of Zogenix
.

Fintepla (fenfluramine, fenfluramine) oral solution, while expanding the clinical development pipeline for the treatment of epilepsy and rare diseases
.

Fintepla, developed by Zogenix, is a low-dose fenfluramine in liquid form
.
Fenfluramine was developed as an appetite suppressant diet pill in the 1960s and was approved in the United States in 1973
.
It may reduce the frequency of seizures by modulating serotonin machinery and sigma-1 receptor activity
.
Fintepla was previously approved by the U.
S.
FDA in June 2020 for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older
.
In March, the drug was approved by the FDA for an expanded indication for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients two years of age and older
.

It may reduce the frequency of seizures by modulating serotonin machinery and sigma-1 receptor activity
.